{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:25:33Z","timestamp":1783592733616,"version":"3.55.0"},"reference-count":69,"publisher":"Bioscientifica","issue":"1","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>S179D prolactin (PRL) is an experimentally useful mimic of naturally phosphorylated human prolactin. S179D PRL, but not unmodified PRL, was found to be anti-angiogenic in both the chorioallantoic membrane and corneal assays. Further investigation using human endothelial in vitro models showed reduced cell number, reduced tubule formation in Matrigel, and reduced migration and invasion, as a function of treatment with S179D PRL. Analysis of growth factors in human endothelial cells in response to S179D PRL showed: a decreased expression or release of endogenous PRL, heme-oxygenase-1, basic fibroblast growth factor (bFGF), angiogenin, epidermal growth factor and vascular endothelial growth factor; and an increased expression of inhibitors of matrix metalloproteases. S179D PRL also blocked signaling from bFGF in these cells. We conclude that this molecular mimic of a pituitary hormone is a potent anti-angiogenic protein, partly as a result of its ability to reduce utilization of several well-established endothelial autocrine growth loops, partly by its ability to block signaling from bFGF and partly because of its ability to decrease endothelial migration. These findings suggest that circulating levels of phosphorylated PRL may influence the progression of cancer and, furthermore, that S179D PRL may be a useful anti-angiogenic therapeutic.<\/jats:p>","DOI":"10.1677\/erc.1.01076","type":"journal-article","created":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T18:08:42Z","timestamp":1144346922000},"page":"95-111","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":30,"title":["A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone"],"prefix":"10.1530","volume":"13","author":[{"given":"Eric","family":"Ueda","sequence":"first","affiliation":[{"name":"1Division of Biomedical Sciences, University of California, Riverside, California 92521, USA"},{"name":"2IPEN-CNEN-Biotechnology Department, Universidade de Sao Paulo, Sao Paulo, CEP 05508\u2013900 Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Ozerdem","sequence":"additional","affiliation":[{"name":"3La Jolla Institute for Molecular Medicine, San Diego, California 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"1Division of Biomedical Sciences, University of California, Riverside, California 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yao","sequence":"additional","affiliation":[{"name":"4Cell Biology and Neuroscience, University of California, Riverside, California 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang Tzu","family":"Huang","sequence":"additional","affiliation":[{"name":"1Division of Biomedical Sciences, University of California, Riverside, California 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Sun","sequence":"additional","affiliation":[{"name":"3La Jolla Institute for Molecular Medicine, San Diego, California 92121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Martins-Green","sequence":"additional","affiliation":[{"name":"4Cell Biology and Neuroscience, University of California, Riverside, California 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bartolini","sequence":"additional","affiliation":[{"name":"2IPEN-CNEN-Biotechnology Department, Universidade de Sao Paulo, Sao Paulo, CEP 05508\u2013900 Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameae M","family":"Walker","sequence":"additional","affiliation":[{"name":"1Division of Biomedical Sciences, University of California, Riverside, California 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2026070905580584800_BALUK-ETAL-2005","doi-asserted-by":"crossref","unstructured":"Baluk\n            P\n          , Hashizume H & McDonald DM 2005 Cellular abnormalities of blood vessels as targets in cancer. Current Opinion in Genetics and Development15102\u2013111.","DOI":"10.1016\/j.gde.2004.12.005"},{"key":"2026070905580584800_BECK-ETAL-2003","unstructured":"Beck\n            MT\n          , Chen NY, Franek KJ & Chen WY 2003 Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Research633598\u20133604."},{"key":"2026070905580584800_BEN-JONATHAN-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Ben-Jonathan\n            N\n          , Mershon JL, Allen DL & Steinmetz RW 1996 Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Reviews17639\u2013669.","DOI":"10.1210\/edrv-17-6-639"},{"key":"2026070905580584800_BEN-JONATHAN-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Ben-Jonathan\n            N\n          , Liby K, McFarland M & Zinger M 2002 Prolactin as an autocrine\/paracrine growth factor in human cancer. Trends in Endocrinology and Metabolism13245\u2013250.","DOI":"10.1016\/S1043-2760(02)00603-3"},{"key":"2026070905580584800_BERGERS-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Bergers\n            G\n          , Song S, Meyer-Morse N, Bergsland E & Hanahan D 2003 Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation1111287\u20131295.","DOI":"10.1172\/JCI200317929"},{"key":"2026070905580584800_BERNICHTEIN-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Bernichtein\n            S\n          , Kinet S, Jeay S, Llovera M, Madern D, Martial JA, Kelly PA & Goffin V 2001 S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not antantagonist. Endocrinology1423950\u20133963.","DOI":"10.1210\/endo.142.9.8369"},{"key":"2026070905580584800_BUSTIN-2000","doi-asserted-by":"crossref","unstructured":"Bustin\n            SA\n          \n          2000 Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. Journal of Molecular Endocrinology25169\u2013193.","DOI":"10.1677\/jme.0.0250169"},{"key":"2026070905580584800_CHEN-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Chen\n            NY\n          , Holle L, Li W, Peirce SK, Beck MT & Chen WY 2002 In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. International Journal of Oncology20813\u2013818.","DOI":"10.3892\/ijo.20.4.813"},{"key":"2026070905580584800_CHEN-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Chen\n            TJ\n          , Kuo CB, Tsai KF, Liu JW, Chen DY & Walker AM 1998 Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology139609\u2013616.","DOI":"10.1210\/endo.139.2.5758"},{"key":"2026070905580584800_CHUN-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Chun\n            TH\n          , Sabeh F, Ota I, Murphy H, McDonagh KT, Holmbeck K, Birkedal-Hansen H, Allen ED & Weiss SJ 2004 MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. Journal of Cell Biology167757\u2013767.","DOI":"10.1083\/jcb.200405001"},{"key":"2026070905580584800_CLAPP-AND-WEINER-1992","doi-asserted-by":"crossref","unstructured":"Clapp\n            C\n           & Weiner RI 1992 A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology1301380\u20131386.","DOI":"10.1210\/endo.130.3.1311239"},{"key":"2026070905580584800_CLAPP-ETAL-1993","doi-asserted-by":"crossref","unstructured":"Clapp\n            C\n          , Martial JA, Guzman RC, Rentier-Delure F & Weiner RI 1993 The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology1331292\u20131299.","DOI":"10.1210\/endo.133.3.7689950"},{"key":"2026070905580584800_CLAPP-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Clapp\n            C\n          , Lopez-Gomez FJ, Nava G, Corbacho A, Torner L, Macotela Y, Duenas Z, Ochoa A, Noris G, Acosta E, Garay E & Martinez de la Escalera G 1998 Expression of prolactin mRNA and of prolactin-like proteins in endothelial cells: evidence for autocrine effects. Journal of Endocrinology158137\u2013144.","DOI":"10.1677\/joe.0.1580137"},{"key":"2026070905580584800_CLEVENGER-AND-PLANK-1997","doi-asserted-by":"crossref","unstructured":"Clevenger\n            CV\n           & Plank TL 1997 Prolactin as an autocrine\/paracrine factor in breast tissue. Journal of Mammary Gland Biology and Neoplasia259\u201368.","DOI":"10.1023\/A:1026325630359"},{"key":"2026070905580584800_CORBACHO-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Corbacho\n            AM\n          , Macotela Y, Nava G, Torner L, Duenas Z, Noris G, Morales MA, Martinez De La Escalera G & Clapp C 2000 Human umbilical vein endothelial cells express multiple prolactin isoforms. Journal of Endocrinology16653\u201362.","DOI":"10.1677\/joe.0.1660053"},{"key":"2026070905580584800_COSS-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Coss\n            D\n          , Kuo CB, Yang L, Ingleton P, Luben R & Walker AM 1999 Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. Endocrinology1405087\u20135094.","DOI":"10.1210\/en.140.11.5087"},{"key":"2026070905580584800_COSS-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Coss\n            D\n          , Yang L, Kuo CB, Xu X, Luben RA & Walker AM 2000 Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. American Journal of Physiology. Endocrinology and Metabolism279E1216\u2013E1225.","DOI":"10.1152\/ajpendo.2000.279.6.E1216"},{"key":"2026070905580584800_COSTLOW-AND-MCGUIRE-1977","doi-asserted-by":"crossref","unstructured":"Costlow\n            ME\n           & McGuire WL 1977 Autoradiographic localization of the binding of 125I-labelled prolactin to rat tissues in vitro. Journal of Endocrinology75221\u2013226.","DOI":"10.1677\/joe.0.0750221"},{"key":"2026070905580584800_DUENAS-ETAL-1999","unstructured":"Duenas\n            Z\n          , Torner L, Corbacho AM, Ochoa A, Gutierrez-Ospina G, Lopez-Barrera F, Barrios FA, Berger P, Martinez de la Escalera G & Clapp C 1999 Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Investigative Ophthalmology and Visual Science402498\u20132505."},{"key":"2026070905580584800_ENGE-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Enge\n            M\n          , Bjarnegard M, Gerhardt H, Gustafsson E, Kalen M, Asker N, Hammes HP, Shani M, Fassler R & Betsholtz C 2002 Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO Journal214307\u20134316.","DOI":"10.1093\/emboj\/cdf418"},{"key":"2026070905580584800_FOLKMAN-1995","unstructured":"Folkman\n            J\n          \n          1995 Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine127\u201331."},{"key":"2026070905580584800_FOLKMAN-AND-DRAMORE-1996","doi-asserted-by":"crossref","unstructured":"Folkman\n            J\n           & D\u2019Amore PA 1996 Blood vessel formation: what is its molecular basis? Cell871153\u20131155.","DOI":"10.1016\/S0092-8674(00)81810-3"},{"key":"2026070905580584800_FRYSTYK-2005","doi-asserted-by":"crossref","unstructured":"Frystyk\n            J\n          \n          2005 The growth hormone hypothesis \u2013 2005 revision. Hormone and Metabolism Research3744\u201348.","DOI":"10.1055\/s-2005-861362"},{"key":"2026070905580584800_FUH-AND-WELLS-1995","doi-asserted-by":"crossref","unstructured":"Fuh\n            G\n           & Wells JA 1995 Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. Journal of Biological Chemistry27013133\u201313137.","DOI":"10.1074\/jbc.270.22.13133"},{"key":"2026070905580584800_GOLDHAR-ETAL-2005","doi-asserted-by":"crossref","unstructured":"Goldhar\n            AS\n          , Vonderhaar BK, Trott JF & Hovey RC 2005 Prolactin-induced expression of vascular endothelial growth factor via Egr-1. Molecular and Cellular Endocrinology2329\u201319.","DOI":"10.1016\/j.mce.2005.01.005"},{"key":"2026070905580584800_HATA-SUGI-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Hata-Sugi\n            N\n          , Kawase-Kageyama R & Wakabayashi T 2002 Characterization of rat aortic fragment within collagen gel as an angiogenesis model; capillary morphology may reflect the action mechanisms of angiogenesis inhibitors. Biological and Pharmaceutical Bulletin25446\u2013451.","DOI":"10.1248\/bpb.25.446"},{"key":"2026070905580584800_HELLSTROM-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Hellstrom\n            M\n          , Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H & Betsholtz C 2001 Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. Journal of Cell Biology153543\u2013553.","DOI":"10.1083\/jcb.153.3.543"},{"key":"2026070905580584800_HOVEY-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Hovey\n            RC\n          , Goldhar AS, Baffi J & Vonderhaar BK 2001 Transcriptional regulation of vascular endothelial growth factor expression in epithelial and stromal cells during mouse mammary gland development. Molecular Endocrinology15819\u2013830.","DOI":"10.1210\/mend.15.5.0635"},{"key":"2026070905580584800_HU-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Hu\n            ZZ\n          , Meng J & Dufau ML 2001 Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. Journal of Biological Chemistry27641086\u201341094.","DOI":"10.1074\/jbc.M102109200"},{"key":"2026070905580584800_HUANG-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Huang\n            KT\n          , Chen YH & Walker AM 2004 Inaccuracies in MTS assays: major distorting effects of medium, serum albumin, and fatty acids. Biotechniques37406, 408, 410\u2013412.","DOI":"10.2144\/04373ST05"},{"key":"2026070905580584800_JACKSON-ETAL-1994","doi-asserted-by":"crossref","unstructured":"Jackson\n            D\n          , Volpert OV, Bouck N & Linzer DI 1994 Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein. Science2661581\u20131584.","DOI":"10.1126\/science.7527157"},{"key":"2026070905580584800_KENYON-ETAL-1996","unstructured":"Kenyon\n            BM\n          , Voest EE, Chen CC, Flynn E, Folkman J & D\u2019Amato RJ 1996 A model of angiogenesis in the mouse cornea. Investigative Ophthalmology and Visual Science371625\u20131632."},{"key":"2026070905580584800_KENYON-ETAL-1997","doi-asserted-by":"crossref","unstructured":"Kenyon\n            BM\n          , Browne F & D\u2019Amato RJ 1997 Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Experimental Eye Research64971\u2013978.","DOI":"10.1006\/exer.1997.0292"},{"key":"2026070905580584800_KHURANA-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Khurana\n            S\n          , Kuns R & Ben-Jonathan N 1999 Heparin-binding property of human prolactin: a novel aspect of prolactin biology. Endocrinology1401026\u20131029.","DOI":"10.1210\/endo.140.2.6677"},{"key":"2026070905580584800_KLINE-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Kline\n            JB\n          , Rycyzyn MA & Clevenger CV 2002 Characterization of a novel and functional human prolactin receptor isoform (delta S1PRLr) containing only one extracellular fibronectin-like domain. Molecular Endocrinology162310\u20132322.","DOI":"10.1210\/me.2001-0033"},{"key":"2026070905580584800_KOCHENDOERFER-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Kochendoerfer\n            SK\n          , Krishnan N, Buckley DJ & Buckley AR 2003 Prolactin regulation of Bcl-2 family members: increased expression of bcl-xl but not mcl-1 or bad in Nb2-T cells. Journal of Endocrinology178265\u2013273.","DOI":"10.1677\/joe.0.1780265"},{"key":"2026070905580584800_KRISHNA-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Krishna\n            MM\n          , Lin Y & Englander SW 2004 Protein misfolding: optional barriers, misfolded intermediates, and pathway heterogeneity. Journal of Molecular Biology3431095\u20131109.","DOI":"10.1016\/j.jmb.2004.08.098"},{"key":"2026070905580584800_KROWN-ETAL-1992","doi-asserted-by":"crossref","unstructured":"Krown\n            KA\n          , Wang YF, Ho TW, Kelly PA & Walker AM 1992 Prolactin isoform 2 as an autocrine growth factor for GH3 cells. Endocrinology131595\u2013602.","DOI":"10.1210\/endo.131.2.1639009"},{"key":"2026070905580584800_KUO-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Kuo\n            CB\n          , Wu W, Xu X, Yang L, Chen C, Coss D, Birdsall B, Nasseri D & Walker AM 2002 Pseudophosphorylated prolactin (S179D PRL) inhibits growth and promotes beta-casein gene expression in the rat mammary gland. Cell and Tissue Research309429\u2013437.","DOI":"10.1007\/s00441-002-0598-8"},{"key":"2026070905580584800_LESSOR-ETAL-1998","doi-asserted-by":"crossref","unstructured":"Lessor\n            T\n          , Yoo JY, Davis M & Hamburger AW 1998 Regulation of heregulin beta-1-induced differentiation in a human breast carcinoma cell line by the extracellular-regulated kinase (ERK) pathway. Journal of Cell Biochemistry70587\u2013595.","DOI":"10.1002\/(SICI)1097-4644(19980915)70:4<587::AID-JCB14>3.0.CO;2-E"},{"key":"2026070905580584800_LI-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Li\n            QJ\n          , Yao M, Wong W, Parpura V & Martins-Green M 2004 The N- and C-terminal peptides of hIL8\/CXCL8 are ligands for hCXCR1 and hCXCR2. FASEB Journal18776\u2013778.","DOI":"10.1096\/fj.02-1175fje"},{"key":"2026070905580584800_LINDAHL-ETAL-1997","doi-asserted-by":"crossref","unstructured":"Lindahl\n            P\n          , Johansson BR, Leveen P & Betsholtz C 1997 Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science277242\u2013245.","DOI":"10.1126\/science.277.5323.242"},{"key":"2026070905580584800_LIU-ETAL-1996","unstructured":"Liu\n            Y\n          , Martindale JL, Gorospe M & Holbrook NJ 1996 Regulation of p21 waf1\/cip1 expression through mitogen-activated protein kinase signaling pathway. Cancer Research5631\u201335."},{"key":"2026070905580584800_LLOVERA-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Llovera\n            M\n          , Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA & Goffin V 2000 Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene194695\u20134705.","DOI":"10.1038\/sj.onc.1203846"},{"key":"2026070905580584800_LOCHNAN-ETAL-1995","unstructured":"Lochnan\n            HA\n          , Buteau H, Richards S, Edery M & Kelly PA 1995 Functional activity of the human prolactin receptor and its ligands. Molecular Cell Endocrinology11491\u201399."},{"key":"2026070905580584800_MARTINS-AND-GREEN-KELLY-1998","doi-asserted-by":"crossref","unstructured":"Martins-Green\n            M\n           & Kelly T 1998 The chicken chemotactic and angiogenic factor (9E3 gene product): its angiogenic properties reside in the C-terminus of the molecule. Cytokine10819\u2013830.","DOI":"10.1006\/cyto.1998.0383"},{"key":"2026070905580584800_MEISTER-ETAL-1992","doi-asserted-by":"crossref","unstructured":"Meister\n            B\n          , Jacobsson G & Elde R 1992 Observations on the localization of prolactin receptor mRNA in rat tissues as revealed by in situ hybridization. Acta Physiologica Scandinavica146533\u2013534.","DOI":"10.1111\/j.1748-1716.1992.tb09458.x"},{"key":"2026070905580584800_MERKLE-ETAL-2000","doi-asserted-by":"crossref","unstructured":"Merkle\n            CJ\n          , Schuler LA, Schaeffer RC Jr, Gribbon JM & Montgomery DW 2000 Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor. Endocrine1337\u201346.","DOI":"10.1385\/ENDO:13:1:37"},{"key":"2026070905580584800_NAYLOR-ETAL-2005","doi-asserted-by":"crossref","unstructured":"Naylor\n            MJ\n          , Oakes SR, Gardiner-Garden M, Harris J, Blazek K, Ho TW, Li FC, Wynick D, Walker AM & Ormandy CJ 2005 Transcriptional changes underlying the secretory activation phase of mammary gland development. Molecular Endocrinology191868\u20131883.","DOI":"10.1210\/me.2004-0254"},{"key":"2026070905580584800_OHTA-AND-YACHIE-2004","doi-asserted-by":"crossref","unstructured":"Ohta\n            K\n           & Yachie A 2004 Development of vascular biology over the past 10 years: heme oxygenase-1 in cardiovascular homeostasis. Journal of Endovascular Therapy11II140\u2013II150.","DOI":"10.1583\/04-1330.1"},{"key":"2026070905580584800_OZERDEM-2005","doi-asserted-by":"crossref","unstructured":"Ozerdem\n            U\n          \n          2005 Targeting neovascular pericytes in neurofibromatosis type 1. Angiogenesis7307\u2013311.","DOI":"10.1007\/s10456-004-6643-3"},{"key":"2026070905580584800_OZERDEM-AND-STALLCUP-2004","doi-asserted-by":"crossref","unstructured":"Ozerdem\n            U\n           & Stallcup WB 2004 Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis7269\u2013276.","DOI":"10.1007\/s10456-004-4182-6"},{"key":"2026070905580584800_PERKS-ETAL-2004","doi-asserted-by":"crossref","unstructured":"Perks\n            CM\n          , Keith AJ, Goodhew KL, Savage PB, Winters ZE & Holly JM 2004 Prolactin acts as a potent survival factor for human breast cancer cell lines. British Journal of Cancer91305\u2013311.","DOI":"10.1038\/sj.bjc.6601947"},{"key":"2026070905580584800_PIETRAS-AND-HANAHAN-2004","doi-asserted-by":"crossref","unstructured":"Pietras\n            K\n           & Hanahan D 2004 A multitargeted, metronomic, and maximum-tolerated dose \u2018Chemo-Switch\u2019 regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. Journal of Clinical Oncology23939\u2013952.","DOI":"10.1200\/JCO.2005.07.093"},{"key":"2026070905580584800_ROYSTER-ETAL-1995","doi-asserted-by":"crossref","unstructured":"Royster\n            M\n          , Driscoll P, Kelly PA & Freemark M 1995 The prolactin receptor in the fetal rat: cellular localization of messenger ribonucleic acid, immunoreactive protein, and ligand-binding activity and induction of expression in late gestation. Endocrinology1363892\u20133900.","DOI":"10.1210\/endo.136.9.7649097"},{"key":"2026070905580584800_SCHROEDER-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Schroeder\n            MD\n          , Brockman JL, Walker AM & Schuler LA 2003 Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology1445300\u20135307.","DOI":"10.1210\/en.2003-0826"},{"key":"2026070905580584800_STRUMAN-ETAL-1999","doi-asserted-by":"crossref","unstructured":"Struman\n            I\n          , Bentzien F, Lee H, Mainfroid V, D\u2019Angelo G, Goffin V, Weiner RI & Martial JA 1999 Opposing actions of intact and N-terminal fragments of the human prolactin\/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. PNAS961246\u20131251.","DOI":"10.1073\/pnas.96.4.1246"},{"key":"2026070905580584800_TAN-ETAL-2005","doi-asserted-by":"crossref","unstructured":"Tan\n            D\n          , Johnson DA, Wu W, Zeng L, Chen YH, Chen WY, Vonderhaar BK & Walker AM 2005 Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short human prolactin receptors in living human cells. Molecular Endocrinology191291\u20131303.","DOI":"10.1210\/me.2004-0304"},{"key":"2026070905580584800_TROTT-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Trott\n            JF\n          , Hovey RC, Koduri S & Vonderhaar BK 2003 Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. Journal of Molecular Endocrinology3031\u201347.","DOI":"10.1677\/jme.0.0300031"},{"key":"2026070905580584800_TUAZON-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Tuazon\n            PT\n          , Lorenson MY, Walker AM & Traugh JA 2002 p21-activated protein kinase gamma-PAK in pituitary secretory granules phosphorylates prolactin. FEBS Letters51584\u201388.","DOI":"10.1016\/S0014-5793(02)02444-4"},{"key":"2026070905580584800_WANG-ETAL-2004","unstructured":"Wang\n            HS\n          , Hwang LL, Sue HF, Lee KM & Chen CT 2004 A simple quantitative method for evaluation of angiogenesis activity. Assay and Drug Development Technologies231\u201338."},{"key":"2026070905580584800_WANG-AND-WALKER-1993","doi-asserted-by":"crossref","unstructured":"Wang\n            YF\n           & Walker AM 1993 Dephosphorylation of standard prolactin produces a more biologically active molecule: evidence for antagonism between nonphosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation. Endocrinology1332156\u20132160.","DOI":"10.1210\/en.133.5.2156"},{"key":"2026070905580584800_WANG-ETAL-1996","doi-asserted-by":"crossref","unstructured":"Wang\n            YF\n          , Liu JW, Mamidi M & Walker AM 1996 Identification of the major site of rat prolactin phosphorylation as serine 177. Journal of Biologial Chemistry2712462\u20132469.","DOI":"10.1074\/jbc.271.5.2462"},{"key":"2026070905580584800_WU-ETAL-2003","doi-asserted-by":"crossref","unstructured":"Wu\n            W\n          , Coss D, Lorenson MY, Kuo CB, Xu X & Walker AM 2003 Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry427561\u20137570.","DOI":"10.1021\/bi034217s"},{"key":"2026070905580584800_WU-ETAL-2005","doi-asserted-by":"crossref","unstructured":"Wu\n            W\n          , Ginsburg E, Vonderhaar BK & Walker AM 2005 S179D prolactin increases vitamin D receptor and p21 through upregulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Research657509\u20137515.","DOI":"10.1158\/0008-5472.CAN-04-3350"},{"key":"2026070905580584800_XU-ETAL-2001","unstructured":"Xu\n            X\n          , Kreye E, Kuo CB & Walker AM 2001 A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Research616098\u20136104."},{"key":"2026070905580584800_XU-ETAL-2003","unstructured":"Xu\n            X\n          , Wu W, Williams V, Khong A, Chen YH, Deng C & Walker AM 2003 Opposite effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin on morphology and the expression of prostate specific genes in the normal rat prostate. Prostate5425\u201333."},{"key":"2026070905580584800_YANG-ETAL-2001","doi-asserted-by":"crossref","unstructured":"Yang\n            L\n          , Kuo CB, Liu Y, Coss D, Xu X, Chen C, Oster-Granite ML & Walker AM 2001 Administration of unmodified prolactin (U-PRL) and a molecular mimic of phosphorylated prolactin (PP-PRL) during rat pregnancy provides evidence that the U-PRL:PP-PRL ratio is crucial to the normal development of pup tissues. Journal of Endocrinology168227\u2013238.","DOI":"10.1677\/joe.0.1680227"},{"key":"2026070905580584800_YANG-ETAL-2002","doi-asserted-by":"crossref","unstructured":"Yang\n            L\n          , Lii S, Kuo B, Buckley A, Buckley D, Chen C, Xu X, Coss D & Walker AM 2002 Maternal prolactin composition can permanently affect epidermal gammadeltaT cell function in the offspring. Developmental and Comparative Immunology26849\u2013860.","DOI":"10.1016\/S0145-305X(02)00036-8"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/13\/1\/0130095.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/13\/1\/95\/150050\/0130095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/13\/1\/95\/150050\/0130095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:58:21Z","timestamp":1783591101000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/13\/1\/95\/26705\/A-molecular-mimic-demonstrates-that-phosphorylated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,3,1]]}},"URL":"https:\/\/doi.org\/10.1677\/erc.1.01076","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3,1]]}}}